Antiviral Effects of Novel 2-Benzoxyl-Phenylpyridine Derivatives

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Mar 25

PMID 32204528

Citations 4

Authors

Yanhong Wei

Haijie Wang

Caili Xi

Ni Li

Dong Li

Chenguang Yao

Ge Sun

Hongmei Ge

Kanghong Hu

Qian Zhang

Affiliations

Soon will be listed here.

Abstract

Coxsackievirus B3 (CVB3) is the most common cause of acute and chronic viral myocarditis, primarily in children, while human adenovirus infections represent a significant cause of morbidity and mortality worldwide, in people of all ages. A series of novel 2-benzoxyl-phenylpyridine derivatives were evaluated for their potential antiviral activities against CVB3 and adenovirus type 7 (ADV7). Preliminary assays indicated that some of these compounds exhibited excellent antiviral effects on both CVB3 and ADV7 viruses; they could effectively inhibit virus-induced cytopathic effects, reduce viral progeny yields, and had similar or superior antiviral activities compared with the control drug, ribavirin. Further, these compounds targeted the early stages of CVB3 replication in cells, including viral RNA replication and protein synthesis, rather than inactivating the virus directly, inhibiting virus adsorption/entry, or affecting viral release from cells. Our data demonstrate that the tested 2-benzoxyl-phenylpyridine derivatives are effective inhibitors of CVB3 and ADV7, raising the possibility that these compounds might be feasible candidates for anti-viral agents.

Citing Articles

Matrine regulates autophagy in ileal epithelial cells in a porcine circovirus type 2-infected murine model.

Wang H, Sun N, Sun P, Zhang H, Yin W, Zheng X Front Microbiol. 2024; 15:1455049.

PMID: 39588099 PMC: 11587598. DOI: 10.3389/fmicb.2024.1455049.

Editorial: Emerging polyoxometalates with biological, biomedical, and health applications.

Aureliano M, Mitchell S, Yin P Front Chem. 2022; 10:977317.

PMID: 36017169 PMC: 9397140. DOI: 10.3389/fchem.2022.977317.

Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants.

Iaconis D, Bordi L, Matusali G, Talarico C, Manelfi C, Cesta M Cell Death Dis. 2022; 13(5):498.

PMID: 35614039 PMC: 9130985. DOI: 10.1038/s41419-022-04961-z.

Syntheses, Characterizations, and Inhibition Activities Against Coxsackievirus B3 of Iodobenzoic Hydrazide Functionalized Hexamolybdates.

Wang L, Guo C, Hu D, Zhao Y, Liu H, Dong Y Front Chem. 2022; 10:841151.

PMID: 35372278 PMC: 8968398. DOI: 10.3389/fchem.2022.841151.

References

Zhang S, Luo Y, Huang D, Fan H, Lu Q, Wo Y . Fatal pneumonia cases caused by human adenovirus 55 in immunocompetent adults. Infect Dis (Lond). 2015; 48(1):40-7. DOI: 10.3109/23744235.2015.1055585. View

Kitazato K, Wang Y, Kobayashi N . Viral infectious disease and natural products with antiviral activity. Drug Discov Ther. 2012; 1(1):14-22. View

Massilamany C, Gangaplara A, Reddy J . Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy. Int J Cardiol. 2014; 177(2):330-339. PMC: 4403007. DOI: 10.1016/j.ijcard.2014.09.136. View

Kemball C, Flynn C, Hosking M, Botten J, Whitton J . Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo. Virology. 2012; 429(1):74-90. PMC: 3358485. DOI: 10.1016/j.virol.2012.04.005. View

Tsuchiya Y, Shimizu M, Hiyama Y, Itoh K, Hashimoto Y, Nakayama M . Antiviral activity of natural occurring flavonoids in vitro. Chem Pharm Bull (Tokyo). 1985; 33(9):3881-6. DOI: 10.1248/cpb.33.3881. View

Fechner H, Pinkert S, Geisler A, Poller W, Kurreck J . Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules. 2011; 16(10):8475-503. PMC: 6264230. DOI: 10.3390/molecules16108475. View

Tan D, Zhu H, Fu Y, Tong F, Yao D, Walline J . Severe Community-Acquired Pneumonia Caused by Human Adenovirus in Immunocompetent Adults: A Multicenter Case Series. PLoS One. 2016; 11(3):e0151199. PMC: 4788423. DOI: 10.1371/journal.pone.0151199. View

Kumar P, Nagarajan A, Uchil P . Analysis of Cell Viability by the MTT Assay. Cold Spring Harb Protoc. 2018; 2018(6). DOI: 10.1101/pdb.prot095505. View

Engelmann I, Coiteux V, Heim A, Magro L, Dewilde A, Dulery R . Severe Adenovirus Pneumonia Followed by Bacterial Septicaemia: Relevance of Co-Infections in Allogeneic Hematopoietic Stem Cell Transplantation. Infect Disord Drug Targets. 2016; 16(1):69-76. DOI: 10.2174/1871526516666160407114623. View

10.

Kim B, Cho J, Jeong P, Lee Y, Lim J, Park K . Benserazide, the first allosteric inhibitor of Coxsackievirus B3 3C protease. FEBS Lett. 2015; 589(15):1795-801. PMC: 7094222. DOI: 10.1016/j.febslet.2015.05.027. View

11.

Crotty S, Cameron C, Andino R . RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A. 2001; 98(12):6895-900. PMC: 34449. DOI: 10.1073/pnas.111085598. View

12.

Naesens L, Lenaerts L, Andrei G, Snoeck R, van Beers D, Holy A . Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother. 2005; 49(3):1010-6. PMC: 549266. DOI: 10.1128/AAC.49.3.1010-1016.2005. View

13.

Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E . Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol. 1998; 160(7):3487-93. View

14.

Thibaut H, De Palma A, Neyts J . Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol. 2011; 83(2):185-92. DOI: 10.1016/j.bcp.2011.08.016. View

15.

Marrugal-Lorenzo J, Serna-Gallego A, Berastegui-Cabrera J, Pachon J, Sanchez-Cespedes J . Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci Rep. 2019; 9(1):17. PMC: 6327057. DOI: 10.1038/s41598-018-37290-3. View

16.

Qiu F, Shen X, Li G, Zhao L, Chen C, Duan S . Adenovirus associated with acute diarrhea: a case-control study. BMC Infect Dis. 2018; 18(1):450. PMC: 6122197. DOI: 10.1186/s12879-018-3340-1. View

17.

Kim B, Kim J, Kim N, Lee W, Lee S, Yun S . Development of anti-coxsackievirus agents targeting 3C protease. Bioorg Med Chem Lett. 2012; 22(22):6952-6. DOI: 10.1016/j.bmcl.2012.08.120. View

18.

Tang Z, Zang N, Fu Y, Ye Z, Chen S, Mo S . HMGB1 mediates HAdV-7 infection-induced pulmonary inflammation in mice. Biochem Biophys Res Commun. 2018; 501(1):1-8. DOI: 10.1016/j.bbrc.2018.03.145. View

19.

Zhai X, Qin Y, Chen Y, Lin L, Wang T, Zhong X . Coxsackievirus B3 induces the formation of autophagosomes in cardiac fibroblasts both in vitro and in vivo. Exp Cell Res. 2016; 349(2):255-263. DOI: 10.1016/j.yexcr.2016.10.020. View

20.

Feld J, Jacobson I, Sulkowski M, Poordad F, Tatsch F, Pawlotsky J . Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int. 2016; 37(1):5-18. PMC: 5216450. DOI: 10.1111/liv.13212. View